Telix Pharmaceuticals Limited

Prostate cancer is the most common male cancer with over 1.4 million cases diagnosed every year, worldwide. At Telix we are committed to helping patients with this disease live longer, better quality lives by facilitating widespread access to advanced imaging and progressing our late-stage therapeutic programs. To learn more visit: telixpharma.com/prostate #makeprostatecancerhistory #PCAM

In his 35 years as a practicing urologist, Dr Paul Dato has seen the field transform with improved screening, diagnostics and therapies helping to halve the U.S. prostate cancer death rate. Here Dr. Dato discusses his experience and some of challenges he has faced, the “revolution” of PSMA theranostics, and what the future might hold for men with this disease. During Prostate Cancer Awareness Month, Telix is sitting down with physicians, advocates and patients to shed light on the current unmet needs in prostate cancer. To read more about what Dr. Dato and Telix are doing to help patients visit: https://lnkd.in/gn-ym4vR

Telix today announces that its IPAX-1 Ph I study has been published in Neuro-Oncology Advances. In the first peer-reviewed publication of this study, Pichler et al. confirmed the investigational therapy TLX101 (131I-IPA), in combination with external beam radiation therapy in recurrent glioblastoma (GBM), had favourable safety and tolerability profile, and demonstrated encouraging preliminary efficacy. Metabolic tumour responses were determined using Telix’s investigational glioma imaging product, TLX101-CDx (Pixclara®, 18F-FET). We recently sat down with IPAX investigator and co-author, Dr Arthur Braat, to discuss the challenges of treating GBM, the most common and aggressive form of primary brain cancer, and why he is supporting further investigation of TLX101. Visit our website for more: https://bit.ly/4dU0dP1 TLX101 and TLX101-CDx have not received marketing authorisation in any jurisdiction. Pixclara brand name is subject to final regulatory approval.

Telix today announces it has submitted a New Drug Application (NDA) to the FDA for TLX101-CDx (Pixclara®), an investigational PET agent for the characterisation of progressive or recurrent glioma (brain cancer) in both adult and pediatric patients. Gliomas are the most common primary brain tumours of the central nervous system, however conventional imaging with MRI often yields inconclusive results and can delay time-sensitive decision-making. TLX101-CDx has the potential to address a critical unmet need to improve diagnosis and management of this disease, particularly in the post-treatment setting. Read more on our website here: https://bit.ly/4g4XzY4

Telix today unveils a new organisational structure, reflecting our focus as a therapeutics-led radiopharmaceutical company committed to precision oncology. The updated business model is designed to optimise the development and commercialisation of theranostic radiopharmaceuticals. We are also pleased to announce new leadership appointments for Kevin Richardson, Richard Valeix and Raphaël (Raph) ORTIZ, and congratulate our colleagues who have taken on new roles at Telix, as we embark on our next phase of evolution. To read the full announcement, visit our website here: https://lnkd.in/gpWE3RA6

Telix has released its results for the half-year ended 30 June 2024. H1 2024 saw Telix continue to grow revenue from Illuccix® with achievements across the theranostic pipeline and in supply chain and manufacturing, positioning the Company for future growth on multiple fronts. To learn more about the results, visit our website, where you can also register for an investor webcast tomorrow morning AEST, later today in Europe and the US: https://bit.ly/3yNAGrv

Telix is pleased to support the #APCC24 Conference taking place next week in Melbourne, Australia. The event will feature four Telix-sponsored sessions delivered by internationally recognised oncologist and ProstACT GLOBAL investigator, Professor Scott Tagawa, MD, delving into the latest advances in prostate cancer theranostics. ⚛️ Review of targeted radionuclide therapy (TRT) for prostate cancer ⚛️ Lutetium - who and when? ⚛️ Is there a role for mets directed therapy in castrate resistant prostate cancer (CRPC)? ⚛️ Novel prostate-specific membrane antigen (PSMA) targeted therapies To view the full program visit the APCC website here: https://lnkd.in/e-jNAJq7 Australian Prostate Centre

Telix will release its Half-Year 2024 results on Thursday 22 August. An investor webcast will be held at 9:00am AEST on Friday 23 August to present financial results and a business update Investors are invited to register for the webcast via our website: https://lnkd.in/gzY8MYvH

An investigator-initiated trial supported by Lightpoint has highlighted the safety profile and early feasibility of using SENSEI® with a 99mTc-PSMA-targeted tracer for the intraoperative detection of metastatic lymph nodes in primary prostate cancer, prior to robot-assisted radical prostatectomy. Building on previous results for sentinel node biopsy, the publication demonstrates the utility of Lightpoint’s drop in gamma probe at initial diagnosis, potentially broadening the application of this technology in the disease, where radioguided surgery with this tracer has typically been performed in the recurrent setting. Further research is now being conducted to confirm the ability of SENSEI and targeted radiation imaging agents to detect micrometastatic prostate cancer during surgery as well as exploring their use in other urologic and non-urologic malignancies. Read the paper below or visit https://lnkd.in/dekia9t for more on Lightpoint and SENSEI